Ontruzant, a biosimilar trastuzumab referencing Herceptin, shows comparable overall survival and cardiac safety, Samsung Bioepis says.
Samsung Bioepis released 3-year follow-up findings of Ontruzant, a biosimilar trastuzumab referencing Herceptin, in early or locally advanced HER2-positive breast cancer, and says it showed comparable overall survival and cardiac safety.
The FDA approved Ontruzant in January for marketing in the United States.
Participants enrolled in an initial phase 3 study received 8 cycles of the biosimilar trastuzumab or the reference medicine concurrently with chemotherapy in the neoadjuvant setting. After surgery, they received additional 10 cycles of the biosimilar trastuzumab or the reference medicine.
After completion of therapy, 367 of these participants (186 in the biosimilar trastuzumab group and 181 in the reference medicine group) were enrolled in the follow-up study. Median follow-up from initiation of study treatment was 40.8 months in the biosimilar trastuzumab group and 40.5 months in the reference medicine group.
Overall survival was 97% in the biosimilar trastuzumab group and 93.6% in the reference medicine group (hazard ratio [HR], 0.39; 95% CI, 0.14-1.12). Event-free survival was 92.5% in the biosimilar trastuzumab group and 86.3% in the reference medicine group (HR, 0.49; 95% CI, 0.26-0.91).
Cardiac events were rare for both treatment groups. There were 3 cases of asymptomatic significant left ventricular ejection fraction (LVEF) decrease (biosimilar trastuzumab, n = 1; reference medicine, n = 2), with all patients recovering with LVEF of 50% or greater. There were no cases of symptomatic congestive heart failure, cardiac death, or other significant cardiac conditions reported in either group.
“With the development of our biosimilar trastuzumab, we aimed to make one of the mainstays of modern cancer therapy more accessible for more people more quickly, and these long-term data underline the importance of that aim,” says Chul Kim, senior vice president and head of clinical sciences division, Samsung Bioepis, in a statement. “We are committed to increasing access to high-quality, life-changing oncology medicines through the development of biosimilars to address some of oncology’s most pressing challenges.”
The drug was first approved by the European Medicines Agency in November 2017, making it the first biosimilar trastuzumab to be approved in the European Union.
The data were presented at the 16th St. Gallen International Breast Cancer Conference 2019 in Austria.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.